CDK4_6 Inhibitors in HR+, HER2-Negative Breast Cancer

CE / CME

Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: May 30, 2024

Expiration: May 29, 2025

Sara A. Hurvitz
Sara A. Hurvitz, MD, FACP
Erica L. Mayer
Erica L. Mayer, MD, MPH
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Woman With Grade 2 ILC and 4 Positive Nodes


A 58-yr-old woman who is postmenopausal, presents with a 5-cm right breast mass with one suspicious node​. Initial breast biopsy reveals ILC, grade 2, with the following biomarkers​: ER 80%, PgR 30%, HER2- by IHC​. Fine-needle aspiration of a palpable right axillary lymph node reveals adenocarcinoma of the breast​ and BRCA testing was negative​.


Patient receives neoadjuvant TC x 6 cycles and then undergoes bilateral mastectomy​. Right mastectomy specimen reveals a 3-cm ILC with minimal chemotherapy effect and 4/15 positive nodes​. She returns to the clinic now to discuss adjuvant treatment options​. 

Which of the following would you select as adjuvant therapy for this patient?